ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology

Glen Rodman  |  December 5, 2023

At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.

Filed under:ACR ConvergenceConditionsGuidanceLegislation & AdvocacyMeeting ReportsPediatric ConditionsProfessional Topics Tagged with:abortionACR Convergence 2023Juvenile Arthritis (JIA)reproductive rights

Clinical Year in Review: 2023

Samantha C. Shapiro, MD  |  December 4, 2023

SAN DIEGO—At ACR Convergence 2023, Philip Seo, MD, MHS, presented an overview of clinical updates in rheumatology from the past year.

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2023ankylosing spondylosisPolymyalgia Rheumatica

The Great Debate 2023

Ruth Jessen Hickman, MD  |  December 4, 2023

SAN DIEGO—Panelists at ACR Convergence 2023 debate the merits of IL-6 inhibitors vs. glucocorticoids for the initial treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic ConditionsVasculitis Tagged with:ACR Convergence 2023PMR FocusRheumPolymyalgia Rheumatica

Large Vessel Vasculitis

Philip Seo, MD, MHS  |  December 1, 2023

SAN DIEGO—The large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, experienced a surge of interest at ACR Convergence 2023. Here, we highlight important points from 10 of the studies presented at this conference.

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:ACR Convergence 2023large-vessel vasculitisPolymyalgia Rheumatica

Reduced-Dose Glucocorticoids for GPA & Microscopic Polyangiitis

Arthritis & Rheumatology  |  December 1, 2023

SAN DIEGO—In a study titled Real-Life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis, Nagle et al. evaluated the efficacy and safety of the reduced-dose glucocorticoid regimen in a real-world setting. Background/Purpose Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with…

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:AAVAAV FocusRheumACR Convergence 2023Arthritis & RheumatologyCorticosteroidsgranulamatosis with polyangiitismicroscopic polyangiitis (MPA)Research

Risks of Severe HCQ Non-Adherence

Arthritis & Rheumatology  |  November 30, 2023

Lower HCQ Serum Levels Associated with SLE Flare, Damage & Mortality Background & Objectives: Nguyen et al. set out to assess the consequences of severe non-adherence to hydroxychloroquine (HCQ) by measuring hydroxychloroquine serum levels, risks of systemic lupus erythematosus (SLE) flares, damage and mortality over five years of follow-up. Methods: The Systemic Lupus Erythematosus International…

Filed under:Biologics/DMARDsConditionsSystemic Lupus Erythematosus Tagged with:Arthritis & RheumatologyHydroxychloroquine (HCQ)Research

Pediatric Clinical Year in Review: 2023

Samantha C. Shapiro, MD  |  November 29, 2023

SAN DIEGO—Too many excellent pediatric rheumatology studies to squeeze into one talk? What a good problem to have. Dr. Ardoin first highlighted baricitinib in juvenile idiopathic arthritis.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2023

Top Research in ANCA-Associated Vasculitis Presented at ACR Convergence 2023

Philip Seo, MD, MHS  |  November 21, 2023

SAN DIEGO—Vasculitis expert and former editor of The Rheumatologist, Dr. Philip Seo gives us his picks for the 10 most important abstracts in ANCA-associated vasculitis to come out of ACR Convergence 2023.

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:AAVAAV FocusRheumACR Convergence 2023

Doctor & Patient: A Study in Relapsing Polychondritis

Jason Liebowitz, MD, FACR  |  November 15, 2023

SAN DIEGO—Marcela Ferrada, MD, who most recently was on faculty with the National Institutes of Health (NIH), Bethesda, Md., discussed relapsing polychondritis (RP), a condition that she herself has.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2023

All That Is Old—& New: Treatment Implications for Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  November 7, 2023

EULAR 2023 (MILAN)—Over the past several years, a plethora of new treatments for patients with rheumatoid arthritis (RA) has emerged, while older treatments still play a large role in therapy for many patients. At the EULAR 2023 session titled Rheumatoid Arthritis: New Small Molecules and Old DMARDs, several speakers presented abstracts comparing different treatment effects…

Filed under:Meeting ReportsRheumatoid Arthritis Tagged with:EULAR 2023RA Resource CenterRheumatoid Arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 70
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences